Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma

被引：1

作者：

Broeckelmann, Paul J. ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Cologne, Germany

[3] German Hodgkin Study Grp GHSG, Cologne, Germany

[4] Max Planck Inst Biol Ageing, Max Planck Res Grp Mech DNA Repair, Cologne, Germany

[5] Univ Hosp Cologne, Fac Med, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany

[6] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Kerpener Str 62, D-50937 Cologne, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期

关键词：

anti-PD1; Hodgkin lymphoma; pembrolizumab;

D O I：

10.1111/bjh.19534

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-PD1-based first-line treatment holds great promise in classical Hodgkin lymphoma. The management of immune-related adverse events in the context of time-limited combined checkpoint blockade and chemotherapy administered in curative intent is a challenge. Kuczmarski and Lynch provide a case-based approach to key toxicities observed in this setting.

引用

页码：22 / 24

页数：3

共 50 条

[21] Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Yamauchi, N.
Maruyama, D.
ANNALS OF ONCOLOGY, 2025, 36 (04) : 356 - 358
[22] Clinical biomarkers of response to anti-PD-1 first-line treatment in an Italian patient cohort
Di Pietro, Francesca Romana
Verkhovskaia, Sofia
Mastroeni, Simona
Carbone, Maria Luigia
Abeni, Damiano
Di Rocco, Zorika Christiana
Sama, Nicola
Zappala, Albina Rita
Marchetti, Paolo
De Galitiis, Federica
Failla, Cristina Maria
Fortes, Cristina
JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (SUPPL 1)
[23] Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma
Sickinger, Marie-Therese
von Tresckow, Bastian
Kobe, Carsten
Engert, Andreas
Borchmann, Peter
Skoetz, Nicole
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (01):
[24] The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
Barrington, Sally F.
Trotman, Judith
LANCET HAEMATOLOGY, 2021, 8 (01): : E80 - E93
[25] SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment
Bastos Oreiro, Mariana
Martin, Reyes
Gomez, Pilar
Lopez Munoz, Nieves
Rodriguez, Antonia
Liebana, Marta
Navarro, Belen
Sanchez-Gonzalez, Blanca
Mari, Pilar
Perez de Oteiza, Jaime
Gutierrez, Antonio
Bento, Leyre
Domingo Domenech, Eva
Vidal, Maria Jesus
Del Campo, Raquel
Perez Ceballos, Elena
Infante, Maria
Roldan, Alicia
Garcia Belmonte, Daniel
Santero, Miriam
Sureda, Anna
Sanz, Ramon Garcia
CANCERS, 2021, 13 (10)
[26] Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
Alencar, Alvaro J.
Moskowitz, Craig H.
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 599 - 600
[27] Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma
Alvaro J. Alencar
Craig H. Moskowitz
Nature Reviews Clinical Oncology, 2019, 16 : 599 - 600
[28] Extending anti-PD-1-based options in the setting of Hodgkin lymphoma
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (SUPPL 6) : 131 - 134
[29] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
Han, Fuxin
Wu, Zhaozhen
Chen, Jiaxin
Liu, Meicen
Hu, Yi
CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
[30] Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Bopota, Katerina
Donnelly, Oliver
Borumandi, Farzad
JOURNAL OF CRANIOFACIAL SURGERY, 2023, 34 (03) : E247 - E249

← 1 2 3 4 5 →